ASPIC

envie a um amigo share this

EACR 2022 Congress - Innovative Cancer Science: Translating Biology to Medicine

EACR 2022 Congress - Innovative Cancer Science: Translating Biology to Medicine

1st EACR meeting on the Structural Microenvironment: Breaking down the walls of cancer

EACR-AstraZeneca Virtual Conference ‘Drug Tolerant Persister Cells’

EACR-AstraZeneca Virtual Conference ‘Drug Tolerant Persister Cells’

3rd joint EACR-MRS Conference on Seed and Soil: In Vivo Models of Metastasis

On-line event

 

25-26 January, 2022

 

See more informations here: https://www.eacr.org/conference/seedandsoil2022/index

3rd joint EACR-MRS Conference on Seed and Soil: In Vivo Models of Metastasis

On-line event

 

25-26 January, 2022

 

See more informations here: https://www.eacr.org/conference/seedandsoil2022/index

Novel anti-DLL1 antibody with anti-tumor efficacy against breast cancer

Over 70% of breast cancers (BC) are estrogen receptor-positive (ER+). The Notch ligand Delta-like 1 (DLL1) is a key player in ER+ BCs development and aggressiveness and its overexpression are associated with poor prognosis. In this study, Portuguese researchers developed a novel anti-DLL1 antibody that inhibited tumor growth and liver metastases in a xenograft mouse model. The data suggests that anti-DLL1 immunotherapy can be a promising strategy for ER+ BC treatment.

 

Authors and Affiliations:

Novo anticorpo com propriedades anti-tumorais para cancro da mama

Mais de 70% dos cancros da mama são positivos para o recetor de estrogénio (ER+ BC). A expressão elevada da proteína DLL1 nestes tumores está associada a maior agressividade e por conseguinte a pior prognóstico. Neste estudo, investigadores portugueses desenvolveram um anticorpo capaz de impedir a formação de metástases hepáticas em modelos animais xenotransplantados. Este estudo sugere a inibição da proteína DLL1 como uma nova abordagem no tratamento de cancros da mama positivos para o recetor de estrogénio.

 

Autores e afiliações:

In Silico Approaches: A Way to Unveil Novel Therapeutic Drugs for Cervical Cancer Management

Cervical cancer (CC) is considered the 4th most common cause of death in women worldwide, with over 99% of cases related to human papilloma virus (HPV) infection. According to data from Globocan, in 2020, there were 341 831 deaths, with a higher incidence in developing countries, mainly due to limited financial resources and access to health care. The development of this pathology is related to the expression of the HPV E6 and E7 proteins, since they can interfere with the cellular regulatory mechanisms potentiated by tumor suppressor proteins, such as p53 and pRB proteins.